Recomendaciones sobre los fármacos empleados en pacientes oncohematológicos afectos de COVID-19. Una aproximación a las interacciones farmacológicas entre el tratamiento sintomático y el tratamiento "anti-COVID-19"

Abstract

The SARS-CoV-2 pandemic that exposed our patients to a significant symptom burden made palliative care a necessary tool for the care of these patients. The drugs used to counteract the virus and the treatments used for the control of symptoms have multiple interactions due to both the hepatotrophism of the virus and the metabolism pathways of treatments. With this article we aim to share our experience and some pharmacological recommendations to minimize the potential interactions and side effects of treatments. Much remains to be investigated but we believe that by sharing information between centers we shall be able to provide the best multidisciplinary approach that patients deserve.